April 20, 2015, Shanghai, China--(Business Wire)--Kunming Biomed International (KBI) of southwest China and BTS Research (BTS) of San Diego, California, have announced a major collaboration that appoints BTS as the exclusive importer and distributor of KBI’s non-human primates (NHPs) in western United States. The agreement, signed during the ChinaBio® Partnering Forum held in Shanghai, China on April 15-16, 2015, also provides the platform for the two firms to co-market each other’s research services, enabling each company to provide a broad range of CRO services in China and the US.
The exclusive agreement provides KBI with a direct channel to the US and European pharma markets for its NHPs and contract research organizations services through BTS. This enables BTS to provide low-cost, high-value NHPs directly to its drug development and medical device clients in California and throughout the US. BTS is also uniquely positioned as the only commercial CRO in California to have a license for NHP studies. BTS and KBI are both fully AAALAC accredited, and apply the highest standards of animal welfare and ethics.
“We are very excited to establish this strategic collaboration with BTS Research, a very well respected and successful California-based CRO,” said Dr. Wayne (Wenbao) Li, General Manager of KBI. “This will enable KBI to reach additional clients in the United States for both our high-quality non-human primates as well as our animal models and related services.”
Sami Abunadi, President of BTS Research, added “Our relationship with KBI provides BTS with access to one of the most reliable monkey colonies in the world. And, as the only licensed commercial supplier of non-human primates in California, this enables us to dramatically shorten lead time and offer a cost competitive solution to our clients in the United States as well as our Europe that meets all European and US regulatory requirements,” he continued. “And now, in addition to our wide range of research services, we are able to offer NHPs and related animal models specifically for diabetes, metabolic disease, CNS and CFD therapeutic areas.”
BTS will immediately begin importing the monkeys into the US market and offering them to their clients throughout the US.
About BTS Research
BTS Research, based in San Diego, is a Contract Research Organization (CRO) offering comprehensive services for nonclinical and preclinical studies in state-of-the-art AAALAC-accredited vivarium. BTS services encompass toxicology, pharmacology, cancer, stem cell and metabolism testing in support of GLP and non-GLP drug development in non-human primates, dogs, pigs, rabbits and rodents.
BTS Research offers their expertise as the CRO of choice research partner from discovery through IND with over 55,000 SF of In Vivo and In Vitro space that has been providing quality research since 2001.
About Kunming Biomed
Kunming Biomed International (KBI), located in the southwest of China, is a science-based pharmacology CRO providing preclinical research services for drug discovery and development specializing in non-human primates. The core competency of KBI stems from its expertise in developing and running specialized primate animal models to test drug candidates and medical devices for their pharmacological effects and biocompatible repairs. A large animal colony and many validated disease models (such as Type-2 diabetes, fatty liver, Hyperlipidemia, hypertension, NASH, gastric by-pass, diabetic nephropathy, Parkinson, Alzheimer, arthritis, IBD, stroke, myocardial ischemia, transgenic monkeys etc.) combined with experienced research and scientific study teams offer excellent service which ensures timelines, quality and details. KBI also conducts adjacency studies in PK/PD relationships, bioanalytics, DMPK, histology/pathology, safety pharmacology and preliminary toxicology. KBI offers Chinese speed, China cost-effective studies with the highest western standards and qualities while applying the highest standards of animal welfare and animal ethics. KBI is AAALAC accredited, and is working towards GLP compliance.
